Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Tilsotolimod

Phase 2Small molecule

Tilsotolimod is one of 81 small molecule programs targeting Melanoma. It is currently in Phase 2.

2

Indications

4

Total Trials

2

Active Trials

80

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Head and Neck Squamous Cell CarcinomaActive, not recruiting

MelanomaPhase 2

Active, not recruiting

Head and Neck Squamous Cell CarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Fabhalta

Deltavit

HHyundai Pharmaceutical Co., LTD.

GSK 257049

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Opdualag

Bristol-Myers Squibb

Adjuvant Nivolumab

TThe Netherlands Cancer Institute

PEG-Intron

Talimogene Laherparepvec

Tuoyi

CCoherus Oncology, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2031

Phase 2Recruiting

Melanoma

NCT04126876

Clinical

Trials by Indication[1]

Advanced Cancers1 trial

Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

Terminated·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1·NCT04270864·25 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Completed· AbbVie logo

AbbVie·Phase 1·NCT04196283·30 enrolled

Melanoma1 trial

A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma

Recruiting·AA.J.M. van den Eertwegh·Phase 2·NCT04126876·214 enrolled

Solid Tumors1 trial

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)

Active, not recruiting·IIdera Pharmaceuticals, Inc.·Phase 2·NCT03865082·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tilsotolimod. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tilsotolimod compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tilsotolimod. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AbbVie

Related News